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Abstract
Background: Clinical studies investigating medicinal products need to comply with laws concerning good clinical
practice (GCP) and good manufacturing practice (GMP) to guarantee the quality and safety of the product, to
protect the health of the participating individual and to assure proper performance of the study. However, there
are no specific regulations or guidelines for non-Medicinal Investigational Products (non-MIPs) such as allergens,
enriched food supplements, and air pollution components. As a consequence, investigators will avoid clinical
research and prefer preclinical models or in vitro testing for e.g. toxicology studies.
The aim of this article is to: 1) briefly review the current guidelines and regulations for Investigational Medicinal
Products; 2) present a standardised approach to ensure the quality and safety of non-MIPs in human in vivo
research; and 3) discuss some lessons we have learned.
Methods and results: We propose a practical line of approach to compose a clarifying product dossier (PD), comprising
the description of the production process, the analysis of the raw and final product, toxicological studies, and a thorough risk-
benefit-analysis. This is illustrated by an example from a human in vivo research model to study exposure to air pollutants,
by challenging volunteers with a suspension of carbon nanoparticles (the component of ink cartridges for laser printers).
Conclusion:With this novel risk-based approach, the members of competent authorities are provided with standardised
information on the quality of the product in relation to the safety of the participants, and the scientific goal of the study.
Keywords: Good clinical practice, Good manufacturing practice, Intervention studies, Non-medicinal products, Legislation,
Guidelines
Background and current legislation
Due to some tragedies concerning human medical
intervention studies in the past, the research involving
patients and healthy volunteers is governed by strict
regulation and legislation worldwide [1–3]. The purpose
is to protect the safety of the participants and ensure
credible results. See Table 1 [4].
Nowadays, the Declaration of Helsinki [5] and the
Declaration of Geneva [6] represent the most important
ethics policies of the World Medical Association (WMA)
and are worldwide enforced. They are supported by
practical guidelines focused on adequate Human Subject
Protection (HSP) [5], Good Clinical Practice (GCP) [7],
Good Manufacturing Practice (GMP) [8, 9], and Good
Laboratory Practice (GLP) [4, 8]. See Table 2.
Despite the attempt to harmonize legislation and guide-
lines, there are still significant differences between EU-
member States’ legislation governing clinical research. One
of the reasons is that some Member States feel the need to
* Correspondence: m.berger@amc.uva.nl
1Department of Respiratory Medicine, Academic Medical Centre, University of
Amsterdam, Room F5-280, Meibergdreef 9, 1105 AZ Amsterdam, The
Netherlands
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Berger et al. Respiratory Research  (2016) 17:102 
DOI 10.1186/s12931-016-0413-9
cover a broader scope than the EU Directive related to
clinical research, resulting in country-specific legislation.
There are also differences between the European Union
and other continents, such as the U.S.A.
For clinical research with both registered and non-
registered medicinal products (IMPs), and non-investigational
medicinal products (non-IMPs), definitions and legis-
lation are well described [10, 11]. See Table 3 and Fig. 1.
In contrast to the manifest guidelines for IMP and
non-IMP studies, the guidelines about products that are
the subject of investigation, but not regarded as a medi-
cine, non-Medicinal Investigational Products (non-MIPs)
are undefined.
These are substances used in human intervention
studies to examine the physiological and toxicological
effects of these compounds as opposed to investigat-
ing its pharmaceutical action. These are usually
regarded as challenging agents and shared among the
non-Investigational Medicinal Products (See Tables 3
and 4), with less stringent regulations as compared to
Investigational Medicinal Products [8]. See Table 4.
Unspecific guidelines, regulations and laws for the
quality of these non-Medicinal substances represent a
potential health risk to the individuals participating in
trials and are causing lack of clarity to the investiga-
tors, the pharmacists, and the members of competent
authorities. If the quality of the product cannot be
vouched for, this can lead to unsafe research methods,
even influencing the results and conclusions of a
clinical trial. It is therefore difficult for the investiga-
tors to perform toxicological studies with such chal-
lenging agents.
We propose that, in order to guarantee the safety
of the study subjects and the quality of the research,
the investigators, who use non-Medicinal Investiga-
tional Products, will be encouraged to perform a
thorough analysis and quality check of these products,
including information on the raw product, the pro-
duction proces of the final product, pre-clinal toxicity
data, and a well-founded, product specific risk-benefit
analysis. This information should be clearly docu-
mented and reviewed by the responsible competent
authorities. Since these substances are not medicinal
products, we are introducing an adapted Investiga-
tional Medicinal Product Dossier, simply a Product
Dossier (PD), to supply Ethics Committees and
Competent Authorities with adequate and sufficient
information about the investigational product in a
standardised way.
We will discuss the requirements for such a PD and
will illustrate this with examples from the CARBON-
study. Furthermore, we will share the hurdles that we
have taken and lessons we have learnt to provide a
helping hand when starting studies with non-Medicinal
Investigational Products (non-IMPs).
Carbon-study
Human intervention with carbon nanoparticles
Particulate air pollution is increasingly recognised as
an important causative factor in pulmonary diseases
[12, 13]. To investigate the effect of carbon nano-
particles as a component of air pollution on broncho-
alveolar inflammation, we aimed to develop a safe
and accurate human in vivo research model. To that
end, we developed a suspension of pure carbon nano-
particles, having a comparable size and structure as
Table 1 Regulation and Legislation worldwide
In the U.S.A., the Food and Drug Administration (FDA) is responsible for
the protection of the public health by assuring the safety, efficacy, and
security of drugs, biological products, medical devices, food, and
cosmetics. Based on federal legislation [4], the FDA develops several
guidelines including for Good Clinical Practice (GCP).
In the European Union (EU), the European Commission (EC) is responsible
for the initiation of new legislation, while the European Medicines Agency
(EMA) is responsible for the scientific evaluation of medicines developed
by pharmaceutical producers. The U.S.A., Japan, and the EU are also
represented in the International Conference on Harmonisation of Technical
Requirements for Registration of Pharmaceuticals for Human Use (ICH),
which creates rules and guidelines for the development of new medicinal
products.
Table 2 Current practical guidelines
Good Clinical Practice (GCP)-guidelines comprise proper study design,
generation of credible research data, and safety for study participants,
and correct data management. These issues are assessed by a
competent authority such as a medical ethics committee. Manufacturing
of investigational medicinal products is highly complex. Good
Manufacturing Practice (GMP) guidelines intent to ensure consistency
between batches and adequate documentation of the development
and production of the investigational medicinal products. The GMP
Annex 13 comprises practical guidelines on the quality, production,
quality control, packaging, labelling and shipping of the Active
Pharmaceutical Ingredient (API) and the drug product.
In order to ensure GMP conditions, all information concerning the
topics mentioned in the Annex 13 have to be documented in an
Investigational Medicinal Product Dossier (IMPD). Additionally, in the EU
each product batch needs to be released by a Qualified Person before
the investigational medicinal product is admitted to a clinical trial.
Table 3 Investigational products in clinical research
- Investigational Medicinal Products (IMPs) are registered or non-
registered medicines. New chemical entities, but also the medicinal
product in the comparative study group and placebo’s of the
challenging agents are encountered as IMPs.
- Non-Investigational Medicinal Products (non-IMPs) are medicines
that are not the subject of investigation but supportive to the
trial. These can include rescue medication, medicinal products
given as standard care, or substances that are meant to induce
a physiological response that is necessary to assess the pharmacological
action of the IMP.
Medical devices: will fall outside the scope of this paper.
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soot for bronchial segmental administration. The con-
tent of ink cartridges of laser printers appeared to
fulfil these criteria. It is obvious that this product is
not intended to be used in humans, therefore, we col-
lected information on the raw product (characteristics
and toxicity data), and thoroughly analysed the final
product, in order to make a reliable risk-benefit ana-
lysis on the safety of the final product [14]. The main
goals of the CARBON-study, in which we performed
a bronchial segmental challenge with carbon nanopar-
ticles in healthy volunteers, were:
1. To evaluate the safety of the study participants
according to predefined criteria. Standardized
endpoints were: increase in circulating leukocytes,
adverse events, and complaints such as chest pain,
dyspnea and cough. See also Table 5.
2. To investigate the effect of carbon nanoparticles on
pulmonary and systemic inflammation and
coagulation. Primary endpoint was increase in local
and circulating leukocytes
This study was approved by the institutional ethics
committee and has been registered by the Dutch Trial
Register with number 2976 at http://www.trialregis-
ter.nl/trialreg/admin/rctsearch.asp?Term=2976.
Analysis of the raw material
A major problem with non-Medicinal substances, such as
carbon nanoparticles, is that the raw material is not pro-
duced according to GMP criteria and that thorough
information about the quality of the product is often not
available. Furthermore, there is no information available
about formation of hazardous side products, because the
origin of starting materials and the way of synthesis of the
raw product are not well documented or govern by trade
secrets. Additional analysis of the raw product is therefore
necessary and a risk-based approach is required to decide
which tests are useful to gather sufficient data on the
quality of the product and the suitability for its use in a
clinical study. Because of the unique character of each
product, we need professionals with specific knowledge of
the product, and professionals with knowledge of the
expected physiological action in humans to perform this
thorough analysis. The next important step after finding
the right product, is to perform toxicological studies in
vitro and in animals. See Tables 6, 7 and the CARBON-
Product Dossier (Additional file 1).
Final product: manufacturing, quality control and
stability (See Table 8)
In line with regulation for medicinal products, it is
important to pre-define the criteria the final product
should meet. Furthermore, the manufacturing proces
from raw material to final product and their associated
risks should be described in detail. If possible, it is
preferable to perform the proces controls.
After manufacturing, a quality control has to be
performed on the final product to assess whether the
product meets the pre-defined criteria. For the specifica-
tions of a product, pharmaceutical guidelines may be
helpful. Next to this, as very specific analytical methods
and equipment may be necessary, it is mandatory to
have an agreement with the laboratory about the stand-
ard operating procedures and the quality system of the
laboratory.
Stability testing is required in the development of
Investigational Medicinal Products and it is usually
ongoing during the development. For non-Medicinal
products it is also necessary to perform stability testing
in the final container to exclude formation of hazardous
side products during storage and decrease in activity of
the active compound.
Fig. 1 Overview of investigational products
Table 4 Legislation for non-investigational medicinal products
Although non-IMPs do not fall within the rules for manufacturing of
investigational medicinal products, the EC does require the sponsor
of a study to “ensure that the non-IMPs are in accordance with the
notification/request for authorisation to conduct the trial and that
they are of appropriate quality for the purposes of the trial taking
into account the source of the materials, whether or not they are
the subject of a marketing authorisation and whether they have
been repackaged. The advice and involvement of a Qualified Person
is recommended”.
Berger et al. Respiratory Research  (2016) 17:102 Page 3 of 8
Product specific risk benefit analysis
In the risk-benefit-analysis the current knowledge
about effects in human, animal and in vitro studies
are summarised, followed by discussing (possible)
mechanism of action, selectivity of the mechanism to
target tissue, quality of the product, the concentration
analysis, the quantitative regular daily exposure, the
study design, and analysis and manageability of poten-
tial effects [15]. The investigators should also indicate
how they intend to reduce the risks of the potential
effects to a level that is acceptable in relation to the
scientific importance of the study [16]. Dosage and
route of administration are vital issues in clinical re-
search and part of the risk-benefit analysis. A clear
description is neccesary to assess safety for study
participants. See Table 9 [17–19].
Table 5 Proposed Safety Endpoints for Bronchial Provocation Studies in Humans
Criteria Defined by




Any untoward medical occurrence or effect that at any dose:
- results in death;
- is life threatening (at the time of the event);
- requires hospitalisation or prolongation of existing inpatients’ hospitalisation;
- results in persistent or significant disability or incapacity;
- is a congenital anomaly or birth defect;
- is a new event of the trial likely to affect the safety of the subjects, such as an unexpected outcome of an adverse reaction,
major safety finding from a newly completed animal study, etc.
Blood pressure <100/60 mmHg or > 140/90 mmHg
Heart rate Below 50/min or above 100/min
Temperature Below 34 °C or above 38 °C
Saturation Below 90 %
Laboratory testing More than a 50 % change in blood values concerning liver function, renal function, and bone marrow
FEV1 or PEF Decrease of≥ 20 %
Symptoms e.g. Chest pain, dyspnea, cough, sore throat, dizziness and syncope
Abbreviations: FEV1 forced expiratory volume in 1 s, PEF peak flow
Table 6 Specifications for Printex-U- suspension in saline
Test item Method Acceptance criteria
Description Visual observation Grey suspension




<100 nm vs >100 nm
Nanoparticle Tracking
Analysis (NTA)
> 50 % agglomerates/
particles <100 nm
Purity TEM/EDX 99 % carbon particles,
description of the other
1 %
Arrangement TEM Onion-like






Table 7 CARBON-study; analysis of raw material
Carbon black pigments are the product of incomplete combustion
of hydrocarbons. Depending on the specific manufacturing process
a wide range of different carbon blacks are available, differing in
primary particle size, structure, surface area, and surface chemistry.
As these products are not intended for human use, limited
information was available. We, therefore, extensively tested several
commercially available products for their characteristics by
transmission electron microscopy, nanoparticle tracking analysis,
dynamic light scattering, and asymmetric-flow field-flow fraction-
ation. Figure 2 shows a Transmission Electron Micrograph (TEM)
of Printex-U with a cluster of particles with a primary particle
size < 50 nm. Elemental analysis was performed by transmission
electron microscope energy dispersive X-ray spectroscopy (TEM-EDX).
The copper signal (Cu) is caused by background radiation hitting
the copper sample holder grid on which the particles are deposited
for measurement in the TEM. Unlike the other products, Printex-U
nanoparticles had
a circular shape and onion-like arrangement of atom layers compar-
able to that of carbon nanoparticles in diesel soot. Finally, we also
tested whether our samples were contaminated with endotoxins
by limulus amebocyte lysate test, which showed a contamination
of < 0.01 Eu/ml [14].
Toxicological studies in literature: In vitro analysis of the raw material
showed no direct mutagenic effects, but this could be secondary to
other mechanisms such as oxidative stress or by triggering the
inflammatory processes [22]. For these effects there was a threshold
of 1 mg/m3 [23].
In vivo exposure to rats showed mutations in genes of the epithelial
cells caused by oxidative stress. Also, in situations of impaired lung
clearance (“overload”) and inflammation, some rats developed lung
tumours. Mice and hamsters did not develop tumours. Various cohort
and case-control studies in the U.S. did not show any increases in lung
cancer among carbon black production workers [23].
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Table 8 CARBON-study; analysis of final product
We claimed that the final product had to meet the following
criteria: sterile, pure (no contamination with dust, LPS or metals),
and the main fraction of nanoparticle aggregates had to stay
nanosized when resuspended in saline (Table 6). Carbon particles
tend to form firmly linked aggregates, which in turn join together
to form agglomerates. In order to mimic diesel soot, it was critical
for our research model that the final product contained mostly
loose nanoparticles and nanoparticle aggregates smaller than
100 nm.
The final product was an isotonic suspension of carbon (Printex-U)
and sodium chloride (saline) in sterile water, which was
manufactured under sterile conditions (laminar airflow cabinet)
in three different concentrations: 20, 100, and 200 μg carbon in
10 ml saline. The Printex-U powder was accurately weighed,
mixed with pulverized sodium chloride and suspended in water
for injection. After manufacturing, the product was sterilized in
an autoclave (121 °C, 15 min), and sonicated for 5 min directly
before administration to the study participant. Manufacturing,
packaging, labelling, and batch certification was done by a
qualified pharmacist.
The final product and matching placebo consisting of sterilized saline
were tested for characteristics, contamination (heavy metals, dust,
endotoxins), and stability.
The stability data showed an increase in particle agglomerates in
time. More specifically, when analyzed 1 week after manufacturing,
the main part of the particles were smaller than 100 nm, but after
1 month the number of clusters with a larger size was increased.
Therefore, we decided to make a fresh sample for each study
participant at a maximum of 1 week before administration on the
study day.
Table 9 CARBON-study; design, dosage, administration
In order to measure the single effect of the carbon nanoparticles,
we selected neutral, apolar, round, onion-like, and pure carbon nano
particles which resemble the carbon particles in air pollution concerning
particle characteristics. We aimed the dosage of the final-product to be in
line with normal, daily life exposure concentrations. Dosages were calcu-
lated according to the European Medicines Agency (EMA) First-In-Man
(FIM) guidelines based on the No Observed Adverse Effect Level (NOAEL)
in non-clinical safety studies adjusted with allometric factors. These
dosages are comparable with the mean exposure concentration of PM 2.5
(particles smaller than 2.5 μm) during public fireworks at New Year’s Day at
the first hour of the year, as measured by the Dutch National Air Quality
Monitoring Network and previous research in the Netherlands by Strak et
al. [17]
We used the well-described and safe method of bronchial segmental
challenge [18, 19] to deliver the nanoparticles to the lungs. An
important advantage of this model, as compared to inhalation of diesel
exhaust in an inhalation chamber, is that the exposure is limited to only
one component (carbon nano particles) in only one subsegment of the
lung, thereby reducing the risk of generalized bronchoconstriction. In
the past we safely performed bronchial segmental challenges with
house dust mite allergen and lipopolysaccharide in healthy subjects
as well as patients with mild asthma [18, 19]. Based upon the thorough
analysis of the final product to be used and the careful considerations
regarding the dosage and method of administration, the institutional
ethics committee approved the study.







Toxicity studies in vitro, animals, humans
Final product
Manufacturer/Pharmacist


















Administration route (reduce safety risks if possible)
Mechanism of action (tissue specificity)
Analysis of potential effect
Manageability of potential effects
Estimate the risk of side effects
Pre-define how to manage potential effects
Dosage (based on First-In-Man (FIM) guidelines
based on the No Observed Adverse Effect Level
(NOAEL) in non-clinical safety studies adjusted
with allometric factors)
Quantitative regular daily exposure
Study design (e.g. dose-escalation or pilot study)
Subject characteristics (medical history, age etc.)
Appoint an independent data safety monitoring
board
Predefine safety endpoints (Table 6)
Perform/report interim analyses on safety criteria
during the study.
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Product dossier
All the collected information and test results on the
product should be systematically gathered into a
product dossier (PD). In line with an Investigational
Medicinal Product Dossier (IMPD), this dossier
should include information about the raw material,
the final product, manufacturing procedures, quality
control including used techniques, pharmacological
data (dosage, administration route), pre-clinical tox-
icity data, clinical data, and a risk-benefit analysis. The
PD is part of the documents submitted to the competent
authorities. See Additional file 1 for the Product Dossier of
the CARBON-study and Table 10 for the practical
checklist.
Discussion and lessons learned
Research with non-Medicinal Investigational Products e.g.
allergens, rhinoviruses, endotoxins, carbon nanoparticles
and physiological substances such as lactate is
challenging for investigators as well as members of
competent authorities. An important reason is, that
specific guidelines and regulations required for this
type of research are lacking.
Therefore, we strongly suggest that investigators supply
the Ethics Committee with a Product Dossier (PD),
thereby providing standardised information about the
required aspects of the non-Medicinal Investigational
Product. This dossier comprises production, quality,
and toxicological information about the raw material
and the final product, and a risk-benefit analysis for
the specific target group in the proposed study. Such
a PD should be composed in collaboration with
professionals equipped with product-specific and toxi-
cological knowledge.
In light of the risk-benefit-analysis of the CARBON-
study, we analysed whether carbon nanoparticles
would be able to cause bronchoconstriction, pulmon-
ary inflammation and coagulation activation to the
study participants [20, 21]. We decreased these risks
as much as possible by adjusting research design
(escalating-dose), route of administration (localized,
bronchial segmental deposition) and adjusting the
dosages to relatively normal daily exposures. Natur-
ally, safety endpoints were closely monitored and
documented by the investigators and assessed by an
independent Data Safety Monitoring Board (DSMB).
(See Table 5).
Considering the accountability of the Ethics Committee,
it is comprehensible that it has additional concerns,
requests, and requirements to guarantee the safety of
individuals. Fortunately, we were offered the opportunity
to give further information during a face-to-face meeting
with the Committee, which helped to take away major
concerns.
Fig. 2 Transmission Electron Microscopic (TEM) image of Printex-U. A cluster of particles with a primary particle size of < 50 nm is shown
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Although we performed interim analysis after comple-
tion of each dosage-group, which was assessed by a Data
Safety Monitoring Board, it would have been more
conscientious if the Ethics Committee was also in-
formed about the interim analysis. In retrospect, we also
should have challenged one person per study day
instead of two, in order to better monitor possible
adverse reactions.
Another lesson we learned, is that the risk-benefit
analysis should comprise information about pre-
clinical toxicological studies on both the raw material
and the final product. For the CARBON-study, there
was pre-clinical toxicological information available
about the raw product, but we omitted to perform
these studies with the final product.
After thorough preparation, the CARBON-study was
successfully completed, and showed that bronchial
segmental challenge with carbon nanoparticles up to a
maximum of 100 μg is safe and well tolerated.
Conclusion
In order to guarantee safety for study participants
and to ensure credible research data and harmonisa-
tion of human interventional research, we have pro-
vided a point-by-point line of approach (summarised
in Table 10) for clinical trials investigating non-
Medicinal substances, including instructions on how
to compose a Product Dossier for the Ethics Commit-
tee to assess. One should keep in mind that each
non-Medicinal Investigational Product needs its own
specific, multidisciplinary analysis. With this paper we
intend to draw the attention of the public and gov-
ernment to this issue, in order to stimulate the imple-
mentation of this line of approach as common
practice for human interventional research with non-
Medicinal substances.
Additional file
Additional file 1: Product Dossier. (DOC 5473 kb)
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